文献速递乳腺技术与安全US

基于三维次谐波辅助测压的乳腺癌新辅助化疗反应早期预测

Early Prediction of the Breast Cancer Response to Neoadjuvant Chemotherapy Based on Intratumoral Interstitial Fluid Pressure using 3-D Subharmonic-Aided Pressure Estimation.
PubMed 文献 · Ultrasound Med Biol · 2026-07-19

研究发现肿瘤与相邻正常组织间SHAPE压力梯度在pCR与非pCR组间存在显著差异,30%完成时预测pCR的AUC为0.85;联合肿瘤体积参数后AUC升至0.98。

要点

  • SHAPE压力梯度在化疗完成30%时对pCR预测效能最高,AUC为0.85。
  • 联合肿瘤体积参数与SHAPE梯度,30%时预测pCR的AUC可达0.98。
  • SHAPE梯度在0%、10%、30%时均可区分pCR与非pCR,可用于早期疗效监测。

核心结论

  • SHAPE压力梯度独立或联合肿瘤体积参数可用于乳腺癌新辅助化疗反应的早期预测。
  • 在30%化疗完成时SHAPE预测效能最优,pCR的AUC为0.85,RR的AUC为0.79。
  • 联合肿瘤体积参数后,30%化疗完成时pCR预测AUC提高至0.98,RR预测AUC提高至0.84。

研究设计与样本

  • 采用GE Logiq E9设备及Definity造影剂行三维超声造影,在化疗完成0%、10%、30%三个时间点检查。
  • 以术后病理完全缓解pCR及影像学反应RR(肿瘤体积缩小≥90%)作为疗效评价的参考标准。

关键影像表现/征象

  • 利用超声造影剂次谐波信号幅值与静水压间的反向线性关系,通过SHAPE估算肿瘤与相邻正常组织间的压力梯度。
  • SHAPE压力梯度在pCR与非pCR组间于0%、10%、30%化疗完成时均存在显著差异(p值分别为0.03、0.03、0.001)。
  • SHAPE压力梯度在RR与非RR组间于30%化疗完成时存在显著差异(p=0.007)。

诊断标准与关键数值

  • 30%化疗完成时SHAPE预测pCR的AUC为0.85,预测RR的AUC为0.79。
  • 30%化疗完成时联合肿瘤体积参数与SHAPE梯度预测pCR的AUC为0.98,预测RR的AUC为0.84。
  • SHAPE压力梯度在0%化疗完成时即可区分pCR与非pCR(p=0.03)。

临床应用与阅片要点

  • 可利用化疗完成30%时的SHAPE压力梯度联合肿瘤体积参数对乳腺癌新辅助化疗pCR进行高精度预测。
  • SHAPE压力梯度在化疗早期(0%完成时)即可提供pCR区分信息,有助于提前调整治疗策略。
  • 该技术依赖三维超声造影与次谐波信号分析,操作时需确保造影剂浓度与声压参数标准化以保证压力估算可重复。

局限性

  • 原文未提供SHAPE压力估算的绝对阈值用于临床直接判断,仅提供组间比较与AUC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Elevated intratumoral interstitial fluid pressure (IFP) may negatively impact the efficacy of neoadjuvant chemotherapy (NAC). This study aimed to predict the breast cancer response to NAC based on intratumoral IFP using 3D contrast-enhanced ultrasound (CEUS) with subharmonic-aided pressure estimation (SHAPE). This prospective study enrolled breast cancer patients undergoing NAC from two clinical sites. 3D CEUS was performed at 0%, 10%, and 30% of NAC completion using a GE Logiq E9 with Definity. The pressure gradients between the tumor and adjacent normal tissue were estimated by SHAPE, utilizing the inverse linear relationship between the ultrasound contrast agent's subharmonic signal amplitude and hydrostatic pressure. The obtained SHAPE gradients were evaluated for the prediction of pathological complete response (pCR) and radiological response (RR, tumor volume reduction ≥90%), using t-test and receiver operating characteristic curve analysis. Additionally, the effect of incorporating tumor volume into the SHAPE gradient was evaluated. This study included thirty-seven patients. SHAPE gradients were significantly different between pCR and non-pCR at 0% (p = 0.03), 10% (p = 0.03), and 30% (p = 0.001) completion of NAC, and between RR and non-RR at 30% (p = 0.007) completion of NAC. The optimal predictive performance for SHAPE was achieved at 30% NAC completion, yielding area under the curve (AUC) values of 0.85 for pCR and 0.79 for RR. By combining the tumor volume-based parameters and SHAPE gradient, AUCs were 0.98 for pCR and 0.84 for RR predictions at 30% NAC completion. SHAPE gradient, independently or combined with tumor volume may aid in the early prediction of breast cancer NAC response.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Choi, Dogan, Wessner, et al. Early Prediction of the Breast Cancer Response to Neoadjuvant Chemotherapy Based on Intratumoral Interstitial Fluid Pressure using 3-D Subharmonic-Aided Pressure Estimation. Ultrasound Med Biol. 2026. PMID: 42471280. doi:10.1016/j.ultrasmedbio.2026.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。